Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02955888
Recruitment Status : Terminated (Unsatisfactory rate of recruitment)
First Posted : November 4, 2016
Last Update Posted : December 8, 2020
Sponsor:
Information provided by (Responsible Party):
Liminal BioSciences Ltd.

Brief Summary:
This is a Phase 2, multi-center, double blind, placebo controlled study to evaluate the safety and tolerability of PBI-4050, and its effects on the pancreatic, pulmonary functions and on various biomarkers in Cystic Fibrosis patients with abnormal glucose tolerance. Patients with abnormal glucose tolerance have elevated glucose level either at 1 hour or 2 hour during an Oral Glucose Tolerance Test (OGTT). The Main study will include 24 weeks of treatment with PBI-4050 or matching placebo. At the end of the treatment period, patients will have the option of participating in a 24-week Extension study.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: PBI4050 Drug: Placebo Phase 2

Detailed Description:

This is a Phase 2, multi-center, double blind, placebo controlled study to evaluate the safety and tolerability of PBI-4050, and its effects on the pancreatic, pulmonary functions and on various biomarkers in Cystic Fibrosis patients with abnormal glucose tolerance. Patients with abnormal glucose tolerance have elevated glucose level either at 1 hour or 2 hour during an Oral Glucose Tolerance Test (OGTT).

A total of 90 patients will be enrolled for study participation. A Data Safety Monitoring Board (DSMB) will continually review individual patients safety data obtained from the 90 patients. When the first 15 patients have completed at least 1 month of study treatment, the DSMB will meet formally to determine whether additional patients may be enrolled, the study should continue with changes or if the study should be stopped. In addition, the DSMB will review the PK data and may recommend dose adjustment based on the PK results.

The total duration of study participation for each patient is at least 32 weeks, including up to 4 weeks of a screening period, 24 weeks of study treatment and 4 weeks of safety follow-up.

Patients who choose to participate in the open label extension will be in the study for an additional 24 weeks of study treatment and 4 weeks of safety follow-up (for a total of 56 weeks).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Actual Study Start Date : January 3, 2017
Actual Primary Completion Date : February 2018
Actual Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: PBI4050
Four 200 mg capsules (total 800 mg) administered orally, once daily.
Drug: PBI4050
Investigational Medicinal Product

Placebo Comparator: Placebo
Four 200 mg capsules (total 800 mg) administered orally, once daily.
Drug: Placebo
Comparator




Primary Outcome Measures :
  1. Number of Subjects with Adverse Events (Combined Main Study and Extension Study Participation) [ Time Frame: Baseline to 1 Year ]
    Adverse Event data (including abnormal laboratory values) collected up to final follow-up (30 days after last dose of study drug). Serious Adverse Events that were ongoing at the follow-up visit will be followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition.


Secondary Outcome Measures :
  1. Change from Baseline in glucose level following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  2. Change from Baseline of insulin-secretion following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation) [ Time Frame: Up 1 Year ]
  3. Change from Baseline of HbA1C following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  4. Change from Baseline in pulmonary function parameters (FEV1 ) (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  5. Change from Baseline in pulmonary function parameters ( FVC) (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  6. Change from Baseline in pulmonary function parameters (FEV1/FVC ratio) (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  7. Change from Baseline in pulmonary function parameters (Forced Expiratory Flow (FEF25%-75%)) (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  8. Change from baseline in weight (Combined Main Study and Extension Study Participation) [ Time Frame: Up to1 Year ]

Other Outcome Measures:
  1. Changes from baseline in fibrotic and inflammatory biomarkers in blood (Combined Main Study and Extension Study Participation) [ Time Frame: Up to 1 Year ]
  2. Changes from baseline in fibrotic and inflammatory biomarkers in urine (Combined Main Study and Extension Study Participation) [ Time Frame: Up to1 Year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is 18 years of age or older at screening.
  2. Patient has a documented and confirmed CF diagnosis.
  3. Patient has performed an OGTT for diagnosis of INDENT, IGT and de novo CFRD within 12 months prior to screening visit.
  4. Patient has a Body Mass Index (BMI) of at least 17 kg/m2.
  5. Patient has signed written informed consent.
  6. Patient is able and willing to self-monitor blood glucose level at home.
  7. Female patients of childbearing potential must have a negative pregnancy test (serum or urine) and agree to use adequate birth control from screening throughout the study and for the 30 days after the last study drug administration.
  8. If a male patient has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for the 30 days after the last study drug administration.

Exclusion Criteria:

  1. Patient has recent or ongoing infection requiring intravenous treatment with an anti-infective agent within 30 days before screening.
  2. Patient is concurrently taking high dose of ibuprofen (>30 mg/kg) or is using corticosteroids (except inhaled and topical corticosteroids).
  3. Patient is currently using weight-loss medications.
  4. 4. Patient has used any moderate/potent inhibitor of cytochrome P450 (CYP) 2C9 isozyme or strong inhibitor of CYP3A isozyme within 30 days prior to the first study drug administration.
  5. Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 Upper Limit of Normal (ULN) or total bilirubin above ULN at screening.
  6. Patient has a history of chronic alcohol or other substance abuse as determined at screening that may prevent study compliance based on Investigator judgment.
  7. History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
  8. Patient has unstable chronic heart failure that has required change in therapy within 2 months prior to screening.
  9. Patient with known non-controlled history of infection with Human Immunodeficiency Virus (HIV) and/or active Hepatitis.
  10. Woman who is pregnant, breast-feeding or planning a pregnancy during the course of the study.
  11. Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.
  12. Patient has any condition that, in the Investigator's opinion, is likely to interfere with study conduct and compliance.
  13. Patient has participated in an investigational clinical trial within 30 days (or 5 half-lives, whichever is longer) prior to screening visit.
  14. Patient is under insulin and/or repaglinide treatment at screening/baseline

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02955888


Locations
Layout table for location information
Canada, British Columbia
St. Paul's Hospital - Pacific Lung Health Centre (PLHC)
Vancouver, British Columbia, Canada
Canada, Nova Scotia
Queen Elizabeth II Health Science Center
Halifax, Nova Scotia, Canada
Canada, Ontario
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Canada, Quebec
Institut de Recherches Cliniques de Montréal (IRCM)
Montreal, Quebec, Canada
Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Canada
Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval (IUCPQ)
Quebec, Canada
Sponsors and Collaborators
Liminal BioSciences Ltd.
Investigators
Layout table for investigator information
Study Chair: John Moran, MD Liminal BioSciences Ltd.
Layout table for additonal information
Responsible Party: Liminal BioSciences Ltd.
ClinicalTrials.gov Identifier: NCT02955888    
Other Study ID Numbers: PBI-4050-CT-9-07
First Posted: November 4, 2016    Key Record Dates
Last Update Posted: December 8, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Glucose Intolerance
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases